Lexaria Bioscience Corp. announced on September 27, 2024, that it has received approval from an independent review board for human pilot study #3. This study will investigate a DehydraTECH-processed version of tirzepatide, the active ingredient in Zepbound®, in an oral dose format.
The approval is a crucial step, allowing the company to move forward with human trials for its proprietary drug delivery platform. Subject recruitment for the study is expected to begin shortly, with the first dosing anticipated in late October.
This development positions Lexaria to evaluate the potential of its DehydraTECH technology to offer an oral alternative to injectable GLP-1 drugs, addressing patient preferences and potentially improving adherence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.